Utilize patient tumor samples to generate PDX models that preserve the native tumor heterogeneity, microarchitecture, and complex TME stromal components.
Learn More →Creative Biolabs' macrophage-involved immuno-oncology models for in vivo testing assist in accelerating critical decision-making and validating therapeutic mechanisms through the utilization of advanced humanized myeloid-enabled xenografts and engineered polarization assessment protocols. The primary objective of this service is the provision of precise, quantitative, and translationally relevant data concerning the impact of therapeutic agents on tumor associated macrophages (TAMs). This approach moves beyond rudimentary efficacy assessment to validate the core mechanism of action, which is imperative for regulatory submission and subsequent clinical success.
Various immunotherapies and anticancer drugs have achieved certain success in cancer treatment, and preclinical evaluation of these drugs and therapies is an essential step before being applied to clinical settings. However, there is a limited number of models available to evaluate the interaction between the human immune system and tumors. Evidence shows that macrophages are powerful immune effector cells that play important functions in tumor immunotherapy. Given the active role of macrophages in therapeutic strategies, they have become potential targets for improved cancer treatment. Therefore, it is crucial to develop macrophage-involved immuno-oncology models for in vivo testing.
Initiate a confidential consultation to delineate project-specific solutions.
Fig.1 Macrophages play an important role in cancer. 1
To evaluate the effectiveness against tumors in animal models, Creative Biolabs succeeded in developing macrophage-involved immuno-oncology models for in vivo testing. We employ the co-inoculation approach to generate macrophage-involved immuno-oncology models co-inoculated with CD3+ T cells, induced macrophage, and cancer cells. Based on this, we provide multiple types of macrophage-involved immune-oncology models for global customers' immediate use. In addition, we are confident in providing customized solutions to develop a model that is appropriate for your diverse demands. Noteworthy, we also offer other types of immune-oncology models (DCs-involved immune-oncology models) to support your projects. Together with our top-ranking research team, we have more confidence in helping every customer to:
| Strains | Mouse models |
|---|---|
| General strains | B-NDG; BRG; C57BL/6-RG; CIEA BRG; CIEA NOG; NCG; NOG; NRG; NOD-RG; NSG; NSI |
| MHC-affected strains with genetic alterations | DRAGA; HUMAMICE; NOG-dKO or NOG-B2Mnull, IAnull; NOG I-Abeta <-/->; NSG-A2/DR1; NSG-B2Mnull IA IEnull; NSG-(KbDb)null IAnull |
| Genetically modified strains for cytokine overexpression | BRGST; hIL2-NOG; MISTRG; MISTRG6; NOG-EXL; NSG-SGM3 |
| Other genetically modified strains | BRGS; BRGSKW-v; NBSGW; NOG-pRorc γc; NSG-W41; TKO |
Our myeloid models provide superior capability to facilitate research on the immune regulatory properties of the tumor microenvironment. This enables deep analysis of macrophage-T-cell cross-talk and therapeutic resistance mechanisms unique to the TME.
These humanized systems are excellent models to replicate the dynamics of human immune system interactions with tumors. This fidelity dramatically improves the predictive validity of your preclinical data compared to simpler, less relevant murine alternatives.
The engrafted human macrophages and immune cells are highly sensitive in response to therapeutic stimuli. This ensures that even subtle drug effects and low PK/PD signatures are reliably detectable, providing clearer efficacy readouts.
Our optimized cytokine-enabled mouse strains provide an extensive experimental window duration. This allows for long-term PK/PD assessments, chronic dosing, and comprehensive analysis of therapeutic resistance and relapse mechanisms within a single study.
Explore strategic partnership opportunities - Request a detailed project quotation.
A: These systems incorporate functional human TAMs within the tumor microenvironment, enabling the direct quantification of macrophage reprogramming and phagocytic induction. This higher-fidelity approach significantly reduces the translational gap observed with standard, non-myeloid-enabled xenograft models.
A: Humanized models facilitate the direct investigation of human-specific targets like CD47 and CSF1R in a relevant in vivo context. The utilization of human immune components ensures that the observed therapeutic mechanism is directly transferable to clinical application.
Utilize patient tumor samples to generate PDX models that preserve the native tumor heterogeneity, microarchitecture, and complex TME stromal components.
Learn More →Leverage our extensive catalog of established CDX lines or develop a custom model from your proprietary cell line. CDX models offer unparalleled standardization, high reproducibility, and are ideal for early-stage, high-throughput screening and establishing initial PK/PD relationships.
Learn More →As a leading company in the tumor research industry, Creative Biolabs is constantly developing more effective tools to evaluate anti-cancer drugs and immunotherapies in preclinical examination. If you want to know more details about our macrophage-involved immune-oncology models for in vivo testing, please get in touch with us without hesitation. We will try our best to deliver the best service to you.
Reference